Articles tagged "Dosage"

2022 American Transplant Congress
Thymoglobulin Induction Protocol: Quality Improvement Project via Clinical Audit
S. Mouawad¹, J. Dann¹, A. Kumar², S. Rao³
¹University of Virginia Health System, Charlottesville, VA, ²Nephrology, University of Virginia, Charlottesville, VA, ³University of Virginia, Charlottesville, VA
*Purpose: The aim of our study was to analyze the adequacy of the thymoglobulin (rATG) induction protocol for the expanding and higher complexity kidney transplant…
2022 American Transplant Congress
Post-Kidney Transplant Valacyclovir or Valganciclovir for EBV Prophylaxis: A Randomized Controlled Trial
P. S. Verghese¹, A. Matas², S. Chinnakotla², M. Evans³, H. Balfour Jr⁴
¹Pediatric Nephrology, Northwestern University, Feinberg School of Medicine, Minneapolis, MN, ²Surgery, University of Minnesota Medical School, Minneapolis, MN, ³Biostatistics, University of Minnesota, Minneapolis, MN, ⁴Lab Medicine & Pathology, University of Minnesota, Minneapolis, MN
*Purpose: EBV viremia post-kidney transplant (KTx) has no proven prophylaxis.*Methods: In this randomized, open-label trial [NCT01329185], adult and pediatric recipients were randomly assigned (1:1) to…
2022 American Transplant Congress
Optimal Dose of Anti-Thymocyte Globulin to Improve Allograft and Patient Survival After Kidney Transplantation: Analysis from Korean Organ Transplantation Registry Data
Y. Shim, H. Kwon, Y. Kim, H. Kwon, J. Jung, Y. Ko, S. Lim, S. Shin
Surgery, Asan Medical Center, Seoul, Seoul, Korea, Republic of
*Purpose: The optimal dose of anti-thymocyte globulin (ATG) as an induction regimen in Asian kidney recipients is unclear.*Methods: Using Korean Organ Transplantation Registry database, we…
2022 American Transplant Congress
Reduction of Rabbit Anti-Thymocyte Globulin Dosing for Induction of Kidney Transplant During the COVID-19 Pandemic
C. Burrelli¹, S. Gundling¹, D. Ecabert¹, R. Powell¹, A. Padiyar¹, K. Andreoni¹, K. Chavin², A. Bixby¹
¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²University Hospitals Cleveland Medical Center / Case Western Reserve, Cleveland, OH
*Purpose: Rabbit anti-thymocyte globulin (rATG) is a polyclonal antibody utilized for induction immunosuppression in high immunologic risk kidney transplant recipients. However, the optimal total dose…
2022 American Transplant Congress
Real-Life Tacrolimus Levels Are Associated with Biopsy-Proven Acute Rejection After the First Year Post-Kidney Transplantation
S. Meziyerh, T. van Gelder, D. van der Helm, P. J. van der Boog, J. W. de Fijter, D. J. Moes, A. P. de Vries
LUMC, Leiden, Netherlands
*Purpose: Evidence to recommend specific target concentrations for immunosuppression beyond the first year of kidney transplantation (KT) is limited. We correlated real-life exposure data of…
2022 American Transplant Congress
Conversion of Tacrolimus Immediate Release to LCP Tacrolimus in Obese Kidney Transplant Recipients
J. Newman, N. Patel, S. Patel, T. Sprague, E. Andrade, N. Rao, F. Bartlett, D. DuBay, V. Rohan, M. Casey, D. Taber
MUSC, Charleston, SC
*Purpose: Data describing the safety, efficacy and conversion ratio of tacrolimus immediate release (IR) to LCP-tacrolimus (LCP) in obese patients (BMI > 30) is lacking.…
2022 American Transplant Congress
Artificial Intelligence Based Dosing of Tacrolimus in Liver Transplantation: Prospective, Randomized Phase 2 Trial
A. Zarrinpar¹, C. Ho², C. Warren¹, J. Khong², M. Lee², S. Duarte¹, K. Andreoni¹, M. Johnson¹, N. Battula³, D. McKimmy¹, T. Beduschi¹
¹Surgery, University of Florida, Gainesville, FL, ²Mechanical and Aerospace Engineering, University of California, Los Angeles, CA, ³Surgery, University of Oklahoma, Oklahoma City, OK
*Purpose: Inter- and intra-individual variability in calcineurin dose requirements necessitates empirical clinician-titrated dosing that frequently results in deviation from target ranges, particularly during the critical…
2022 American Transplant Congress
Use of Dd-cfdna to Guide Tapering of Immunosuppression Therapy in Kidney Transplant Recipients
G. Osuchukwu¹, A. Trevino¹, L. Beretich², S. McCormick², N. Kaur², R. White², P. Gauthier²
¹Victoria Kidney and Dialysis Associates, Victoria, TX, ²Natera, Inc., Austin, TX
*Purpose: Continuous administration of immunosuppressive therapy (IST) is required to avoid allograft rejection in transplant recipients. However, these therapeutic interventions can lead to significant side…
2022 American Transplant Congress
Incidence of Dapsone-Induced Methemoglobinemia in Solid Organ Transplant Recipients
D. Quan¹, R. Gordon¹, J. Lee¹, D. Khoshabafard², A. Han¹
¹Pharmacy, UCSF Medical Center, San Francisco, CA, ²Clinical Phamacy, UCSF School of Pharmacy, San Francisco, CA
*Purpose: The purpose of this study was to determine the incidence of dapsone-induced methemoglobinemia in solid organ transplant recipients.*Methods: This was a single-center retrospective cohort…
2022 American Transplant Congress
Safety and Efficacy of Darbepoetin Alfa Dosing Strategies in Renal Transplant Recipients
J. A. Solis, A. Dao, T. Sam, T. Ma, A. F. Yango, B. V. Fischbach, N. Wilson
Baylor University Medical Center, Dallas, TX
*Purpose: Post-transplant anemia (PTA) is a common phenomenon in renal transplant recipients (RTR). There are currently no consensus guidelines for PTA, however patients are commonly…

1
2
3
…
9
Next Page »